Clinical trials
High-Risk Localized Prostate Cancer clinical trials
Below are recruiting high-risk localized prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 107 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05313815Recruiting
Test a stronger prostate radiation boost for high-risk prostate cancer
This trial studies whether giving a moderate “boost” dose of radiation to the prostate—along with radiation to the pelvic area—can better control high-risk localized prostate cancer. You may benefit if you have high-risk disease and can safely receive radiation.
Toronto, OntarioAges 18 years+ - NCT05344235Recruiting
Study of very short radiation schedules for prostate cancer
This observational study looks at how well men with localized prostate cancer do when treated with an unusually short radiation approach. It may help doctors understand which patients benefit most by tracking outcomes and imaging over time.
Leuven, Vlaams BrabantAges Any age - NCT05348876RecruitingPhase 4
Darolutamide plus standard hormone therapy for high-risk prostate cancer
This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.
Vijayawada, Andhra PradeshAges 18 years+ - NCT05396872Recruiting
Decision-making study about gene testing for advanced prostate cancer
This study looks at how Veterans with advanced prostate cancer make decisions about gene testing and possible targeted treatments, and how patients and caregivers understand the information. It may help by improving decision support for people facing germline and tumor testing choices.
San Francisco, CaliforniaAges 18 years+ - NCT05448547RecruitingPhase 3
Tested curative vs conservative treatment for older men with high-risk prostate cancer
This Phase 3 study compares an immediate curative treatment plan versus a more conservative approach in men age 75 and older with newly diagnosed, high-risk prostate cancer. The goal is to see which strategy controls the cancer while better protecting quality of life.
CopenhagenAges 75 years+ - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT05593497RecruitingPhase 2
Study of hormone therapy plus capivasertib before prostate surgery
This Phase 2 trial tests whether adding capivasertib to intensified hormone therapy (leuprolide plus abiraterone) given before prostate surgery can improve outcomes for men with high-risk localized prostate cancer that has a specific tumor marker (PTEN loss). You would also have extra blood tests, scans, and a tissue biopsy for tumor testing.
West Los Angeles, CaliforniaAges 18 years+ - NCT05726292RecruitingPhase 2
Enzalutamide plus relacorilant versus placebo for high-risk prostate cancer
This study tests whether adding relacorilant to enzalutamide (a hormone-blocking treatment) helps control high-risk localized prostate cancer better than enzalutamide plus a dummy pill. It may help prevent the cancer from growing or spreading by targeting a hormone pathway in addition to standard treatment.
Chicago, IllinoisAges 18 years+ - NCT05806515RecruitingPhase 2
Carboplatin before surgery for high-risk BRCA prostate cancer
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
Anchorage, AlaskaAges 18 years+ - NCT06029036RecruitingPhase 2
Darolutamide and ADT before prostate surgery
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
BeijingAges 18–75 - NCT06122584RecruitingPhase 3
PSMA PET scan for high-risk prostate cancer before surgery
This trial tests if a special PET scan using PSMA-1007 can find prostate cancer spread in men who have just been diagnosed with high-risk prostate cancer and plan to have surgery. The scan may help doctors better understand the cancer before removing the prostate and lymph nodes.
NancyAges 18 years+ - NCT06130995RecruitingPhase 1
Relugolix and enzalutamide for high-risk prostate cancer
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
Oklahoma City, OklahomaAges 18 years+ - NCT06220435Recruiting
Radiation therapy for very high-risk localized prostate cancer
This trial tests radiation therapy for men with very high-risk prostate cancer that hasn't spread. It aims to see if targeting the tumor with radiation can help control the cancer in this highest risk group.
LundAges 18 years+ - NCT06235151RecruitingPhase 3
Copper-64 PSMA PET scan for newly diagnosed prostate cancer
This trial tests a special PET scan that uses copper-64 to help find prostate cancer cells. It may help doctors better plan surgery and lymph node removal for men with higher-risk prostate cancer.
Homewood, AlabamaAges 18 years+ - NCT06282588RecruitingPhase 2/Phase 3
Advanced imaging-guided treatment for high-risk prostate cancer
This trial uses a special PET scan (PSMA PET/CT) and a genetic test (Decipher) to decide the best treatment for high-risk prostate cancer that hasn't spread outside the pelvis. You'll receive standard radiation and hormone therapy, possibly with an extra drug (darolutamide).
Wilrijk, AntwerpAges 18 years+ - NCT06325046Recruiting
Adaptive radiation therapy for localized prostate cancer
This trial tests a type of radiation that adapts to your body's changes during treatment. It is for men with low- to intermediate-risk prostate cancer that hasn't spread.
Albert Lea, MinnesotaAges 18 years+ - NCT06331013Recruiting
CyberKnife Radiation for Prostate Cancer
This trial tests a high-precision radiation treatment (CyberKnife SBRT) for prostate cancer that is still within the prostate. It aims to see if a very short course of radiation works well with fewer side effects.
MilanAges 18–80 - NCT06384222RecruitingPhase 2
MRI scan to monitor response to abiraterone before prostate surgery
This trial tests whether a special MRI scan can show how well the drug abiraterone works against high-risk prostate cancer before surgery. If you have high-risk prostate cancer that hasn't spread, you might be able to take abiraterone for a few months and then have a prostatectomy, with the MRI helping your doctor see the drug's effect.
San Francisco, CaliforniaAges 18 years+ - NCT06389786Recruiting
Using a new PET scan to find cancer spread before prostate surgery
This trial tests a special PET/MRI scan that may help doctors see if prostate cancer has spread to nearby lymph nodes before surgery. It could help guide treatment decisions for men with high-risk prostate cancer.
Jacksonville, FloridaAges 30–85 - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Phoenix, ArizonaAges 18 years+ - NCT05918263Recruiting
Exercise to slow prostate cancer in men on active surveillance
This trial tests whether moderate exercise can help keep low-risk prostate cancer from growing in men who are monitoring their cancer instead of treating it right away. It may be especially helpful for men with certain risk factors like obesity or being Black or African American.
Boston, MassachusettsAges 18 years+ - NCT06625970RecruitingPhase 3
Darolutamide and high-dose radiation for high-risk prostate cancer
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
BrestAges 18–80 - NCT06636682RecruitingPhase 2
Vaccine for men with high-risk prostate cancer after surgery
This trial tests a personalized vaccine (FK-PC101) given after prostate removal surgery for men with high-risk prostate cancer. It aims to see if the vaccine can help prevent the cancer from coming back without the need for additional hormone therapy or radiation.
Chicago, IllinoisAges Any age - NCT06834152Recruiting
Online adaptive radiation for localized prostate cancer
This trial tests a new way to deliver high-precision radiation to the prostate using daily MRI or CT scans to adjust the treatment based on your exact anatomy. It aims to make radiation more accurate and reduce side effects.
Heidelberg, Baden-WurttembergAges 18 years+
Hear when a new High-Risk Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high-risk localized prostate cancer?
- Yes. Clin2 currently lists 107 recruiting high-risk localized prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high-risk localized prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high-risk localized prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.